Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized Survanta for neonatal respiratory distress syndrome
IRCT20120728010430N10Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of beractant in respiratory distress syndrome (RDS) and hyaline membrane disease (RDS) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Duration of non-invasive ventilation, Chronic lung disease and 4 more. Started Dec 2019; status: completed.
02
Drugs
beractant
03
Conditions
respiratory distress syndrome (RDS)hyaline membrane disease (RDS)
Beyond the preview
Go deeper on IRCT20120728010430N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120728010430N10.